KR20220079582A - 임신성 당뇨병에 대한 대사 프로파일 스크리닝 - Google Patents

임신성 당뇨병에 대한 대사 프로파일 스크리닝 Download PDF

Info

Publication number
KR20220079582A
KR20220079582A KR1020227014354A KR20227014354A KR20220079582A KR 20220079582 A KR20220079582 A KR 20220079582A KR 1020227014354 A KR1020227014354 A KR 1020227014354A KR 20227014354 A KR20227014354 A KR 20227014354A KR 20220079582 A KR20220079582 A KR 20220079582A
Authority
KR
South Korea
Prior art keywords
subject
marker
diabetes
test sample
metabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227014354A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 제이. 쿠스
Original Assignee
더 리전츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리전츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리전츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20220079582A publication Critical patent/KR20220079582A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020227014354A 2019-10-11 2020-10-09 임신성 당뇨병에 대한 대사 프로파일 스크리닝 Pending KR20220079582A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914294P 2019-10-11 2019-10-11
US62/914,294 2019-10-11
PCT/US2020/055020 WO2021072222A1 (en) 2019-10-11 2020-10-09 Metabolic profile screening for gestational diabetes

Publications (1)

Publication Number Publication Date
KR20220079582A true KR20220079582A (ko) 2022-06-13

Family

ID=75436783

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227014354A Pending KR20220079582A (ko) 2019-10-11 2020-10-09 임신성 당뇨병에 대한 대사 프로파일 스크리닝

Country Status (8)

Country Link
US (1) US20240085432A1 (https=)
EP (1) EP4022299A4 (https=)
JP (1) JP7607951B2 (https=)
KR (1) KR20220079582A (https=)
CN (1) CN114761794A (https=)
AU (1) AU2020361608A1 (https=)
CA (1) CA3157057A1 (https=)
WO (1) WO2021072222A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114167066B (zh) * 2022-01-24 2022-06-21 杭州凯莱谱精准医疗检测技术有限公司 生物标志物在制备妊娠糖尿病诊断试剂中的用途
CN117187381B (zh) * 2023-11-03 2024-02-13 南京医科大学 一种用于妊娠期糖尿病早期辅助诊断的甲基化区域标志物组合及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058142A2 (en) 2003-12-16 2005-06-30 Emory University Diabetes diagnostic
CA2690541A1 (en) * 2007-07-17 2009-01-29 Metabolon, Inc. Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same
WO2012058298A1 (en) * 2010-10-26 2012-05-03 Mayo Foundation For Medical Education And Research Biomarkers of reduced insulin action
EP3094968B1 (en) * 2014-01-15 2020-12-09 The Regents of The University of California Metabolic screening for gestational diabetes
JP2019027885A (ja) 2017-07-28 2019-02-21 国立大学法人千葉大学 妊娠糖尿病の発症リスクの診断用バイオマーカー
US20190310269A1 (en) * 2018-04-04 2019-10-10 Human Longevity, Inc. Systems and methods for measuring obesity using metabolome analysis

Also Published As

Publication number Publication date
AU2020361608A1 (en) 2022-04-21
EP4022299A4 (en) 2023-03-01
JP2022551656A (ja) 2022-12-12
CN114761794A (zh) 2022-07-15
EP4022299A1 (en) 2022-07-06
WO2021072222A1 (en) 2021-04-15
US20240085432A1 (en) 2024-03-14
JP7607951B2 (ja) 2025-01-06
CA3157057A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
Horgan et al. Metabolic profiling uncovers a phenotypic signature of small for gestational age in early pregnancy
Retnakaran et al. Effect of maternal weight, adipokines, glucose intolerance and lipids on infant birth weight among women without gestational diabetes mellitus
Brown et al. Application of one-step IADPSG versus two-step diagnostic criteria for gestational diabetes in the real world: impact on health services, clinical care, and outcomes
Hsieh et al. The association between maternal oxidative stress at mid-gestation and subsequent pregnancy complications
Laughon et al. First trimester uric acid and adverse pregnancy outcomes
Singer et al. Urinary neutrophil gelatinase-associated lipocalin distinguishes pre-renal from intrinsic renal failure and predicts outcomes
AU2010240781B2 (en) Methods for determining maternal health risks
Caglar et al. Sex‐hormone‐binding globulin early in pregnancy for the prediction of severe gestational diabetes mellitus and related complications
Ghaemi et al. Proteomic signatures predict preeclampsia in individual cohorts but not across cohorts–implications for clinical biomarker studies
Nguyen et al. Using proteomics to advance the search for potential biomarkers for preeclampsia: A systematic review and meta-analysis
US20120270747A1 (en) Method of predicting risk of pre-term birth
Bozkurt et al. Adiponectin and leptin at early pregnancy: association to actual glucose disposal and risk for GDM—a prospective cohort study
Roiz‐Hernández et al. Human chorionic gonadotropin levels between 16 and 21 weeks of pregnancy and prediction of pre‐eclampsia
Zhang et al. Prediction of severe preeclampsia in machine learning
Zhou et al. A critical review of proteomic studies in gestational diabetes mellitus
Wang et al. Risk prediction model of gestational diabetes mellitus in a Chinese population based on a risk scoring system
Tamblyn et al. Serum and urine vitamin D metabolite analysis in early preeclampsia
Saglam et al. Diagnostic value of glycemic markers HbA1c, 1, 5-anhydroglucitol and glycated albumin in evaluating gestational diabetes mellitus
Zorba et al. Visfatin serum levels are increased in women with preeclampsia: a case-control study
Auricchio et al. Predicting role of GFAP and UCH-L1 biomarkers in spontaneous subarachnoid hemorrhage: a preliminary study to evaluate in the short-term their correlation with severity of bleeding and prognosis
Fan et al. Correlation between high serum ferritin levels and adverse pregnancy outcomes in women with gestational diabetes mellitus
KR20220079582A (ko) 임신성 당뇨병에 대한 대사 프로파일 스크리닝
Dai et al. Risk stratification of women with gestational diabetes mellitus using mutually exclusive categories based on the International Association of Diabetes and Pregnancy Study Groups criteria for the development of postpartum dysglycaemia: a retrospective cohort study
Huhn et al. The utility of early gestational OGTT and biomarkers for the development of gestational diabetes mellitus: an international prospective multicentre cohort study
Demircan Sezer et al. Comparison of maternal and umbilical cord blood HIF-1 α and nitric oxide levels in early and late onset preeclamptic pregnancies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000